Last reviewed · How we verify

Sitosterolemia — Treatment Landscape & Competitive Intelligence

Sitosterolemia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sitosterolemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zetia EZETIMIBE Merck & Co. HMG-CoA Reductase Inhibitor [EPC] Niemann-Pick C1-like protein 1 2002-01-01
Ezetrol Ezetrol NVP Healthcare Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merck & Co. · 1 drug in Sitosterolemia
  2. NVP Healthcare · 1 drug in Sitosterolemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sitosterolemia:

Cite this brief

Drug Landscape (2026). Sitosterolemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sitosterolemia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing